Inventiva S.A. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of oral small molecule drugs. The company primarily focuses on therapies for non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs. Its flagship clinical asset is lanifibranor, a pan-PPAR agonist that targets all three peroxisome proliferator-activated receptor isotypes to treat NASH by addressing fibrosis, inflammation, and metabolism. Inventiva's pipeline has also included odiparcil for the treatment of mucopolysaccharidoses (MPS), though the company has strategically prioritized its resources toward the late-stage development of lanifibranor. Operating primarily out of France, the company leverages its proprietary drug discovery platform and historical expertise in nuclear receptors, transcription factors, and epigenetic modulation to advance its clinical programs.
